source
- Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pillNovo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
- Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinomaHighlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…